Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma

被引:0
|
作者
Gebhardt, Christoffer
Keller, Laura
Heidrich, Isabel
Koett, Julian
Geidel, Glenn
Abbott, Charles
Boyle, Sean Michael
Pugh, Jason
Chen, Richard
Simon, Ronald
Schneider, Stefan W.
Pantel, Klaus
机构
[1] Univ Med Ctr Hamburg Eppendorf UKE, Skin Canc Ctr, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf UKE, Inst Tumor Biol, Hamburg, Germany
[3] Personalis Inc, Menlo Pk, CA USA
[4] Univ Med Ctr Hamburg Eppendorf UKE, Inst Pathol, Hamburg, Germany
[5] Univ Med Ctr Hamburg Eppendorf UKE, Dept Dermatol, Hamburg, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
9562
引用
收藏
页数:1
相关论文
共 50 条
  • [31] Association Between Metastatic Melanoma Response to Checkpoint Inhibitor Therapy and Tumor-Infiltrating Lymphocyte Classification on Primary Cutaneous Melanoma Biopsies
    Stephens, Michael R.
    Aderbigbe, Oyinade
    Xu, Wei
    Karakousis, Giorgos C.
    Ming, Michael E.
    Chu, Emily Y.
    JAMA DERMATOLOGY, 2023, 159 (02) : 215 - 216
  • [32] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean T.
    Nesline, Mary
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [33] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean
    Nesline, Mary
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
    Andrew Patterson
    Noam Auslander
    Nature Communications, 14
  • [36] Peritoneal melanosis associated with metastatic melanoma previously treated with targeted and immune checkpoint inhibitor therapy
    Sim, Kwang Kiat
    Connell, Katie
    Bhandari, Mayank
    Paton, David
    BMJ CASE REPORTS, 2021, 14 (01)
  • [37] Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma A case report
    Langan, Ewan A.
    Budner, Kaja
    Zillikens, Detlef
    Terheyden, Patrick
    MEDICINE, 2021, 100 (16) : E25513
  • [38] Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma
    Miao, Diana
    Liu, David
    Keliher, Daniel
    Shukla, Sachet
    Schilling, Bastian
    Margolis, Claire
    Smart, Alicia
    Garraway, Levi
    Hodi, Stephen
    Schadendorf, Dirk
    Van Allen, Eliezer M.
    CANCER RESEARCH, 2017, 77
  • [39] IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma
    Jason A. Carter
    Philip Gilbo
    Gurinder S. Atwal
    Nature Medicine, 2019, 25 : 1833 - 1835
  • [40] Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
    Noam Auslander
    Gao Zhang
    Joo Sang Lee
    Dennie T. Frederick
    Benchun Miao
    Tabea Moll
    Tian Tian
    Zhi Wei
    Sanna Madan
    Ryan J. Sullivan
    Genevieve Boland
    Keith Flaherty
    Meenhard Herlyn
    Eytan Ruppin
    Nature Medicine, 2018, 24 : 1942 - 1942